FDA OKs Immunotherapy-BCG Combo for High-Risk Bladder Cancer

(MedPage Today) -- The FDA approved durvalumab (Imfinzi) in combination with bacillus Calmette-Guérin (BCG) for adults with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). The approval was based on results from the phase...
Source
MedPage Today
Opens original article in a new tab



